Colgate Boosts Dividend, Taps Pharma CEO for Board in Strategic Pivot

NEW YORK, NY – March 12, 2026 – Colgate-Palmolive Company today signaled a dual commitment to shareholder stability and strategic innovation, announcing its 63rd consecutive annual dividend increase alongside the appointment of a prominent biopharmaceutical leader to its Board of Directors.

The consumer goods giant raised its quarterly cash dividend to $0.53 per share, a move that reinforces its status as a "Dividend King" with an uninterrupted payout history stretching back to 1895. Simultaneously, the company elected Dr. Christopher Boerner, the Board Chair and CEO of Bristol-Myers Squibb, to its board, a decision that points toward a deeper integration of health sciences into its long-term vision.

A Legacy of Shareholder Returns

Colgate-Palmolive's decision to increase its quarterly dividend, up from $0.52 per share, will be effective in the second quarter of 2026. The new annualized rate of $2.12 per share underscores the company's robust financial health and unwavering focus on delivering value to its investors. The dividend is scheduled to be paid on May 15, 2026, to shareholders of record as of April 20, 2026.

This consistent growth in shareholder returns is a hallmark of the company, which has now increased its dividend for 63 straight years. This track record places it in an elite group of companies known for their reliability, a particularly attractive quality for income-focused investors. The move is supported by strong operational performance, with the company reporting a record $4.2 billion in net cash from operations in 2025. Despite a reported decrease in operating profit last year, largely due to a significant non-cash impairment charge related to its skin health business, the company’s underlying financial strength remains solid.

With a payout ratio based on free cash flow standing at a sustainable 46%, Colgate-Palmolive appears well-positioned to continue this tradition. Its dividend yield, which hovers around 2.2%, remains competitive within the consumer staples sector, holding its own against peers like Procter & Gamble. This latest increase serves as a powerful signal of management's confidence in future earnings and its long-term strategic plan.

A Strategic Prescription for the Boardroom

In a move that captured significant attention, the company also announced a key change in its governance structure. Dr. Christopher Boerner will join the Board of Directors effective March 15, 2026, bringing a wealth of experience from the highest echelons of the biopharmaceutical industry. As the current CEO and Board Chair of Bristol Myers Squibb, Dr. Boerner has a deep background in global commercialization, strategy, and scientific innovation, having also held leadership roles at Seattle Genetics and Genentech.

"We warmly welcome Chris to the Board and look forward to the contributions his exceptional capabilities will bring to our company," said Noel Wallace, Colgate-Palmolive’s Chairman, President and CEO, in a statement.

The appointment coincides with the announcement that Steven A. Cahillane, who recently became CEO of The Kraft Heinz Company, will not stand for reelection to the board at the upcoming annual meeting. The company expressed gratitude for his service. Wallace added, "We express our deepest gratitude to Steve for his dedicated service and invaluable impact on Colgate-Palmolive's success, and we wish him every success going forward."

Dr. Boerner's election is widely seen as more than a routine replacement. It represents a deliberate strategic choice to infuse the board with expertise that directly aligns with the company's mission of "reimagining a healthier future for all people, their pets and our planet."

Bridging Consumer Goods and Health Sciences

The addition of a biopharma executive to the board of a consumer products giant highlights a growing trend: the convergence of everyday wellness with rigorous scientific validation. Dr. Boerner's background in developing and commercializing complex therapies in oncology and immunology could provide invaluable perspective as Colgate-Palmolive seeks to innovate within its own health-focused categories.

This influence is expected to be most pronounced in three key areas. First is the company's flagship Oral Care division, where Colgate is already a global market leader. The push toward more therapeutic and scientifically advanced products—addressing issues from gum health to enamel repair—is a natural fit for a leader versed in clinical development and healthcare marketing.

Second is the company's premium skin health portfolio, which includes brands like EltaMD and PCA SKIN, sold through professional channels. Dr. Boerner’s expertise could help guide strategy in the competitive dermo-cosmetic space, where scientific credibility is paramount.

Perhaps most significantly, his appointment aligns with the explosive growth in the Pet Nutrition segment. The company's Hill's Pet Nutrition brand, which accounts for nearly a quarter of company sales, operates in a market increasingly driven by the "pet humanization" trend. Today's pet owners demand scientifically formulated diets that address specific health needs, from joint support to digestive health. This functional pet food market mirrors the dynamics of the pharmaceutical industry, requiring robust R&D and clear communication of health benefits—areas where Dr. Boerner's experience is directly applicable.

Navigating a Competitive Global Market

These strategic moves come as Colgate-Palmolive navigates a complex and competitive global landscape. While it commands a formidable 41.3% global market share in toothpaste, it faces intense competition from rivals like Procter & Gamble and Unilever across its personal and home care lines. In the high-margin pet nutrition space, its Hill's brand is locked in a tight race with Mars's Royal Canin, making continuous innovation a critical factor for success.

By simultaneously reinforcing its financial stability through a reliable dividend and enhancing its strategic capabilities with top-tier healthcare expertise, Colgate-Palmolive is fortifying its position for the future. The appointment of Dr. Boerner is a clear signal that the company intends to lean heavily into science and health innovation as its primary engine for growth. This strategic pivot could not only reshape product development but also strengthen the company's brand identity as a trusted leader in health and wellness, for every member of the family, including their pets.